39 studies found for:    Belimumab
Show Display Options
Rank Status Study
1 Completed
Has Results
Study of Belimumab Administered Subcutaneously to Healthy Subjects
Condition: Healthy
Interventions: Biological: Single Dose Group: Belimumab IV 240 mg;   Biological: Single Dose Group: Belimumab SC 2 x 120 mg;   Biological: Single Dose Group: Belimumab SC 1 x 240 mg;   Biological: Single Dose Group: Belimumab SC 1 x 200 mg;   Biological: Multiple Dose Group: Belimumab SC 2 x 120 mg weekly;   Biological: Multiple Dose Group: Belimumab SC 1 x 200 mg weekly
2 Terminated Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant
Condition: Desensitization Before Kidney Transplant
Intervention: Drug: Belimumab
3 Terminated
Has Results
Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Intervention: Drug: Belimumab 100 mg SC
4 Completed
Has Results
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Placebo;   Drug: Belimumab 1 mg/kg;   Drug: Belimumab 10 mg/kg
5 Unknown  A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia
Condition: Symptomatic Waldenstroms Macroglobulinaemia
Intervention: Drug: Belimumab
6 Recruiting A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Belimumab plus Early Vaccination;   Biological: Belimumab plus Late Vaccination
7 Completed
Has Results
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Placebo;   Drug: Belimumab 1 mg/kg;   Drug: Belimumab 10 mg/kg
8 Active, not recruiting A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Belimumab 1 mg/kg;   Biological: Belimumab 10 mg/kg
9 Completed Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Biological: belimumab;   Biological: Placebo
10 Recruiting Belimumab in Remission of VASculitis
Condition: Vasculitis
Interventions: Biological: Placebo;   Biological: Belimumab 10 mg/kg;   Drug: Azathioprine
11 Recruiting Belimumab Assessment of Safety in SLE
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Other: Standard therapy
12 Recruiting A Study of Belimumab in the Prevention of Kidney Transplant Rejection
Condition: Transplantation, Organ
Interventions: Drug: Belimumab (10mg/kg) will be given as an intravenous solution over a 1 hour time period week 0, week 2, week 4, week 8, week 12, week 16 and week 20.;   Drug: Placebo (to match belimumab) will be given as an intravenous solution over a 1 hour time period at week 0, week 2, week 4, week 8, week 12, week 16 and week 20.
13 Recruiting Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
14 Active, not recruiting A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 200 mg SC plus standard therapy;   Drug: Standard therapy
15 Recruiting Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
16 Recruiting Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry
Condition: Systemic Lupus Erythematosus
Interventions: Biological: BENLYSTA;   Other: SLE treatment
17 Completed
Has Results
Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: Placebo;   Drug: Belimumab 1 mg/kg;   Drug: Belimumab 4 mg/kg;   Drug: Belimumab 10 mg/kg
18 Completed Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome
Condition: Sjögren's Syndrome
Intervention: Drug: Belimumab
19 Completed
Has Results
A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)
Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo;   Drug: Belimumab 1 mg/kg;   Drug: Belimumab 4 mg/kg;   Drug: Belimumab 10 mg/kg
20 Recruiting Belimumab (BENLYSTA®) Pregnancy Registry
Condition: Systemic Lupus Erythematosus
Intervention: Drug: belimumab

Previous Page Studies Shown (1-20) Next Page (21-39) Show next page of results
Indicates status has not been verified in more than two years